853 related articles for article (PubMed ID: 25829396)
1. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3.
Delwar ZM; Kuo Y; Wen YH; Rennie PS; Jia W
Cancer Res; 2018 Feb; 78(3):718-730. PubMed ID: 29118089
[TBL] [Abstract][Full Text] [Related]
4. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
[TBL] [Abstract][Full Text] [Related]
8. BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.
Bolyard C; Meisen WH; Banasavadi-Siddegowda Y; Hardcastle J; Yoo JY; Wohleb ES; Wojton J; Yu JG; Dubin S; Khosla M; Xu B; Smith J; Alvarez-Breckenridge C; Pow-Anpongkul P; Pichiorri F; Zhang J; Old M; Zhu D; Van Meir EG; Godbout JP; Caligiuri MA; Yu J; Kaur B
Clin Cancer Res; 2017 Apr; 23(7):1809-1819. PubMed ID: 27852701
[No Abstract] [Full Text] [Related]
9. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
10. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
11. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
[TBL] [Abstract][Full Text] [Related]
12. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma.
Xu B; Tian L; Chen J; Wang J; Ma R; Dong W; Li A; Zhang J; Antonio Chiocca E; Kaur B; Feng M; Caligiuri MA; Yu J
Nat Commun; 2021 Oct; 12(1):5908. PubMed ID: 34625564
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract][Full Text] [Related]
14. NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.
Otani Y; Yoo JY; Lewis CT; Chao S; Swanner J; Shimizu T; Kang JM; Murphy SA; Rivera-Caraballo K; Hong B; Glorioso JC; Nakashima H; Lawler SE; Banasavadi-Siddegowda Y; Heiss JD; Yan Y; Pei G; Caligiuri MA; Zhao Z; Chiocca EA; Yu J; Kaur B
Clin Cancer Res; 2022 Apr; 28(7):1460-1473. PubMed ID: 35022322
[TBL] [Abstract][Full Text] [Related]
15. Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps.
Kober C; Rohn S; Weibel S; Geissinger U; Chen NG; Szalay AA
J Transl Med; 2015 Jul; 13():216. PubMed ID: 26149494
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.
Friedman GK; Bernstock JD; Chen D; Nan L; Moore BP; Kelly VM; Youngblood SL; Langford CP; Han X; Ring EK; Beierle EA; Gillespie GY; Markert JM
Sci Rep; 2018 Sep; 8(1):13930. PubMed ID: 30224769
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
18. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition.
Otani Y; Yoo JY; Chao S; Liu J; Jaime-Ramirez AC; Lee TJ; Hurwitz B; Yan Y; Dai H; Glorioso JC; Caligiuri MA; Yu J; Kaur B
Clin Cancer Res; 2020 May; 26(10):2381-2392. PubMed ID: 32139403
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
